Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate

Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences

(2015) Vania Aparecida Mareze et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

(2015) Sri Rezeki Hadinegoro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells

(2015) Amporn Suphatrakul et al.   VACCINE

The dengue vaccine pipeline: Implications for the future of dengue control

(2015) Lauren M. Schwartz et al.   VACCINE

Preclinical and clinical development of a dengue recombinant subunit vaccine

(2015) Susan B. Manoff et al.   VACCINE

Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates

(2015) Dhanasekaran Govindarajan et al.   VACCINE

Analysis of cell-mediated immune responses in support of dengue vaccine development efforts

(2015) Alan L. Rothman et al.   VACCINE

Novel vaccination approach for dengue infection based on recombinant immune complex universal platform

(2015) Mi-Young Kim et al.   VACCINE

Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes

(2015) Monica Poggianella et al.   PLoS Neglected Tropical Diseases

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery

(2014) Ilaria Pepponi et al.   PLoS One

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity

(2014) William B. Messer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection

(2014) M. L. Moi et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

(2014) Chen-Yi Chiang et al.   VACCINE

Challenges in reducing dengue burden; diagnostics, control measures and vaccines

(2013) Sai Kit Lam   Expert Review of Vaccines

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

(2013) D. Weiskopf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles

(2013) Janet C. Lindow et al.   VACCINE

Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice

(2012) L. Gil et al.   JOURNAL OF GENERAL VIROLOGY

M Cell-Targeting Ligand and Consensus Dengue Virus Envelope Protein Domain III Fusion Protein Production in Transgenic Rice Calli

(2012) Tae-Geum Kim et al.   MOLECULAR BIOTECHNOLOGY

Immune Response to Dengue Virus and Prospects for a Vaccine

(2011) Brian R. Murphy et al.   Annual Review of Immunology

Dengue vaccines: progress and challenges

(2011) Beth-Ann G Coller et al.   CURRENT OPINION IN IMMUNOLOGY

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses

(2011) Chen-Yi Chiang et al.   PLoS One

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

(2011) Jorge E. Osorio et al.   VACCINE

Development of dengue DNA vaccines

(2011) Janine R. Danko et al.   VACCINE

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

(2011) Bruno Guy et al.   VACCINE

Polymeric human Fc-fusion proteins with modified effector functions

(2011) David N. A. Mekhaiel et al.   Scientific Reports

Domain III of the envelope protein as a dengue vaccine target

(2010) Maria G Guzman et al.   Expert Review of Vaccines

Fc-Glycosylation Influences Fc  Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12

(2010) D. N. Forthal et al.   JOURNAL OF IMMUNOLOGY

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

(2010) Charmagne G. Beckett et al.   VACCINE

Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification

(2010) Scott J. Balsitis et al.   PLoS Pathogens

A Protective Role for Dengue Virus-Specific CD8+ T Cells

(2009) L. E. Yauch et al.   JOURNAL OF IMMUNOLOGY

Dengue in Vietnamese Infants—Results of Infection‐Enhancement Assays Correlate with Age‐Related Disease Epidemiology, and Cellular Immune Responses Correlate with Disease Severity

(2008) Tran Nguyen Bich Chau et al.   JOURNAL OF INFECTIOUS DISEASES

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

(2008) Chih-Hsiang Leng et al.   MICROBES AND INFECTION

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

(2008) Richard Strasser et al.   PLANT BIOTECHNOLOGY JOURNAL